Myriad Genetics (MYGN) Beat But Not By Enough, Mizuho Says; PT to $34
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Myriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results
May 3, 2016 4:07 PM EDTTotal Revenues of $190.5 Million Adjusted EPS of $0.41 and Diluted EPS of $0.44 Company Issues Fiscal Fourth-Quarter and Updates Fiscal Year 2016 Financial Guidance Â
SALT LAKE CITY, May 03, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced financial results for its fiscal third-quarter 2016, provided an update on recent business highlights, provided fiscal-fourth quarter financial guidance and updated its fiscal year 2016 financial guidance.
"For the fourth consecutive quarter we have exceeded our financial projections and the highlight... More
